Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques

Yanjun Zhang; Haiyan Mao; Ju Li; Jianhua Li; Chen Huang; Jiaxuan Li; Minglei Chu; Fengbo Xue; Linhui Wang; Zhongbiao Fang; Zhen Wang; Jinan Wu; Keda Chen

doi:10.1016/j.virs.2023.05.009

August 2023

. doi: 10.1016/j.virs.2023.05.009

Citation: Yanjun Zhang, Haiyan Mao, Ju Li, Jianhua Li, Chen Huang, Jiaxuan Li, Minglei Chu, Fengbo Xue, Linhui Wang, Zhongbiao Fang, Zhen Wang, Jinan Wu, Keda Chen. Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques .VIROLOGICA SINICA, 2023, 38(4) : 627-630. http://dx.doi.org/10.1016/j.virs.2023.05.009

Delta(B.1.617.2)灭活候选疫苗在恒河猴中能引发针对SARS-CoV-2及其突变体的中和抗体

张严峻 ^a ,
茅海燕 ^a ,
李举 ^b ,
李建华 ^a ,
黄忱 ^a ,
李佳璇 ^c ,
储明磊 ^b ,
薛凤波 ^b ,
王林会 ^b ,
方仲表 ^c ,
王桢 ^a,, ,
吴季南 ^b,, ,
陈科达 ^c,,

a. 浙江省疾病预防控制中心;
b. 宁波荣安生物药业有限公司;
c. 浙江树人学院树兰国际医学院

通讯作者： 王桢, wangzhen@cdc.zj.cn; 吴季南, jinan.wu@aimbio.com; 陈科达, chenkd@zjsru.edu.cn
收稿日期： 2023-02-28
录用日期： 2023-05-23

摘要

由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒病（COVID-19）对全球公共卫生构成重大威胁。疫苗可有效降低COVID-19重症死亡风险。针对SARS-CoV-2的灭活疫苗（Vero细胞，Delta株）在小鼠、大鼠、豚鼠和非人灵长类动物（食蟹猴和恒河猴）中诱导了高水平的SARS-CoV-2特异性中和抗体滴度。该疫苗对原始SARS-CoV-2毒株及其变种（Alpha和Omicron）均显示出良好的交叉中和活性。此外，该疫苗在生产中表现出高生产率和良好的遗传稳定性。这些数据建议在临床试验中进一步评估SARS-CoV-2疫苗。
- SARS-CoV-2
- , 灭活疫苗
- , 中和抗体
- , 循环变异体
- , 恒河猴

Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques

Yanjun Zhang ^a ,
Haiyan Mao ^a ,
Ju Li ^b ,
Jianhua Li ^a ,
Chen Huang ^a ,
Jiaxuan Li ^c ,
Minglei Chu ^b ,
Fengbo Xue ^b ,
Linhui Wang ^b ,
Zhongbiao Fang ^c ,
Zhen Wang ^a,, ,
Jinan Wu ^b,, ,
Keda Chen ^c,,

a. Key Laboratory of Public Health Detection and Etiological Research of Zhejiang Province, Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China;
b. Rong an Bio-pharmaceutical Co, Ltd., Ningbo, 315000, China;
c. Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310000, China

Corresponding author: Zhen Wang, wangzhen@cdc.zj.cn Jinan Wu, jinan.wu@aimbio.com Keda Chen, chenkd@zjsru.edu.cn
Received Date: 28 February 2023
Accepted Date: 23 May 2023

Abstract

Highlights
1. The Delta inactivated vaccine constructed in this study has high immunogenicity and good safety.
2. The inactivated vaccine has good cross-protection against SARS-CoV-2 variants.
3. The vaccine exhibited high productivity and good genetic stability in production.

References
1. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, Flowers MW, Wrammert J, Hussaini L, Ciric CR, Bechnak S, Stephens K, Graham BS, Bayat Mokhtari E, Mudvari P, Boritz E, Creanga A, Pegu A, Derrien-Colemyn A, Henry AR, Gagne M, Douek DC, Sahoo MK, Sibai M, Solis D, Webby RJ, Jeevan T, Fabrizio TP. 2021. Infection and vaccine-induced neutralizing-antibody responses to the sars-cov-2 b.1.617 variants. N Engl J Med, 385:664-666.
2. Katoh K, Misawa K, Kuma K, Miyata T. 2002. Mafft:A novel method for rapid multiple sequence alignment based on fast fourier transform. Nucleic Acids Res, 30:3059-3066.
3. Lee I-J, Sun C-P, Wu P-Y, Lan Y-H, Wang I-H, Liu W-C, Tseng S-C, Tsung S-I, Chou Y-C, Kumari M, Chang Y-W, Chen H-F, Lin Y-S, Chen T-Y, Chiu C-W, Hsieh C-H, Chuang C-Y, Lin C-C, Cheng C-M, Lin H-T, Chen W-Y, Chiang P-C, Lee C-C, Liao JC, Wu H-C, Tao M-H. 2022. Omicron-specific mrna vaccine induced potent neutralizing antibody against omicron but not other sars-cov-2 variants. bioRxiv:2022.2001.2031.478406.
4. Li B, Deng A, Li K, Hu Y, Li Z, Shi Y, Xiong Q, Liu Z, Guo Q, Zou L, Zhang H, Zhang M, Ouyang F, Su J, Su W, Xu J, Lin H, Sun J, Peng J, Jiang H, Zhou P, Hu T, Luo M, Zhang Y, Zheng H, Xiao J, Liu T, Tan M, Che R, Zeng H, Zheng Z, Huang Y, Yu J, Yi L, Wu J, Chen J, Zhong H, Deng X, Kang M, Pybus OG, Hall M, Lythgoe KA, Li Y, Yuan J, He J, Lu J. 2022. Viral infection and transmission in a large, well-traced outbreak caused by the sars-cov-2 delta variant. Nat Commun, 13:460.
5. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. 2021a. Effectiveness of the pfizer-biontech and oxford-astrazeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in england:Test negative case-control study. Bmj, 373:n1088.
6. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. 2021b. Effectiveness of covid-19 vaccines against the b.1.617.2 (delta) variant. N Engl J Med, 385:585-594.
7. Price MN, Dehal PS, Arkin AP. 2010. Fasttree 2——approximately maximum-likelihood trees for large alignments. PLoS One, 5:e9490.
8. Ramakrishnan MA. 2016. Determination of 50% endpoint titer using a simple formula. World J Virol, 5:85-86.
9. Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M. 2022. Limited cross-variant immunity after infection with the sars-cov-2 omicron variant without vaccination. medRxiv.
10. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. 2020. Development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-cov-2. Cell, 182:713-721.e719.
11. Wang N, Zhao D, Wang J, Zhang Y, Wang M, Gao Y, Li F, Wang J, Bu Z, Rao Z, Wang X. 2019. Architecture of african swine fever virus and implications for viral assembly. Science, 366:640-644.
12. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. 2021. Safety and immunogenicity of an inactivated sars-cov-2 vaccine, bbibp-corv:A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 21:39-51.
13. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. 2020. Effect of an inactivated vaccine against sars-cov-2 on safety and immunogenicity outcomes:Interim analysis of 2 randomized clinical trials. Jama, 324:951-960.
14. Xiang T, Wang J, Zheng X. 2022. The humoral and cellular immune evasion of sars-cov-2 omicron and sub-lineages. Virol Sin, 37:786-795.
15. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2017. Ggtree:An r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods in Ecology and Evolution, 8:28-36.
16. Zang J, Zhang C, Yin Y, Xu S, Qiao W, Lavillette D, Wang H, Huang Z. 2022. An mrna vaccine candidate for the sars-cov-2 omicron variant. bioRxiv:2022.2002.2007.479348.
17. Zhang NN, Zhang RR, Zhang YF, Ji K, Xiong XC, Qin QS, Gao P, Lu XS, Zhou HY, Song HF, Ying B, Qin CF. 2022. Rapid development of an updated mrna vaccine against the sars-cov-2 omicron variant. Cell Res, 32:401-403.
18. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. 2021. Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years:A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21:181-192.
19. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med, 382:727-733.
Proportional views
Electronic Supplementary Material

10.1016j.virs.2023.05.009-ESM.docx